Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features
出版年份 2019 全文链接
标题
Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features
作者
关键词
-
出版物
CLINICAL DRUG INVESTIGATION
Volume 39, Issue 8, Pages 805-819
出版商
Springer Science and Business Media LLC
发表日期
2019-07-18
DOI
10.1007/s40261-019-00826-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- 1020-P: Semaglutide-Induced Weight Loss Is Associated with Improved Health-Related Quality of Life and Treatment Satisfaction
- (2019) KARI T. UUSINARKAUS et al. DIABETES
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL
- (2018) Signe Sørensen Torekov CARDIOVASCULAR RESEARCH
- Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
- (2018) Tina Vilsbøll et al. DIABETES OBESITY & METABOLISM
- Clinical pharmacology of glucagon-like peptide-1 receptor agonists
- (2018) Dimitrios Sfairopoulos et al. Hormones-International Journal of Endocrinology and Metabolism
- Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
- (2018) Helena W Rodbard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy
- (2018) Baoying Pang et al. PEPTIDES
- Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement
- (2018) Francesco Giorgino et al. Patient Preference and Adherence
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
- (2018) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- (2018) M Angelyn Bethel et al. Lancet Diabetes & Endocrinology
- Recent updates on GLP-1 agonists: Current advancements & challenges
- (2018) Dilip Sharma et al. BIOMEDICINE & PHARMACOTHERAPY
- Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
- (2018) Gül Bahtiyar et al. Current Diabetes Reports
- Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
- (2018) Raffaella Gentilella et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug development
- (2018) Bo Ahrén Journal of Diabetes Investigation
- Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
- (2018) Yixing Li et al. Current Cardiology Reports
- GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
- (2018) Andrei C. Sposito et al. Cardiovascular Diabetology
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
- (2018) Irene Romera et al. Diabetes Therapy
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials
- (2017) M. Monami et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
- (2017) Bo Ahrén et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
- (2017) Vanita R Aroda et al. Lancet Diabetes & Endocrinology
- Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis
- (2017) Gyeongsil Lee et al. PLoS One
- Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes
- (2016) C. Victor Spain et al. CLINICAL THERAPEUTICS
- Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme
- (2016) M. Yu et al. DIABETES OBESITY & METABOLISM
- A Multicenter Observational Study of Incretin-based Drugs and Heart Failure
- (2016) Kristian B. Filion et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
- (2016) Sheena Kayaniyil et al. Diabetes Therapy
- A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
- (2016) Sheena Kayaniyil et al. Diabetes Therapy
- Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
- (2016) Karel Kostev et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
- (2015) Feng Sun et al. CLINICAL THERAPEUTICS
- Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
- (2015) Sten Madsbad DIABETES OBESITY & METABOLISM
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States
- (2014) Stephen S. Johnston et al. ADVANCES IN THERAPY
- Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
- (2014) Carol Wysham et al. DIABETES CARE
- GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
- (2014) S. Brunton INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer
- (2012) Carlos Alves et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis
- (2012) Feng Sun et al. Experimental Diabetes Research
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- Weight-Related Quality of Life, Health Utility, Psychological Well-Being, and Satisfaction With Exenatide Once Weekly Compared With Sitagliptin or Pioglitazone After 26 Weeks of Treatment
- (2011) J. H. Best et al. DIABETES CARE
- Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No
- (2011) Sten Madsbad European Journal of Internal Medicine
- The Pharmacologic Basis for Clinical Differences among GLP-1 Receptor Agonists and DPP-4 Inhibitors
- (2011) Javier Morales POSTGRADUATE MEDICINE
- Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily
- (2009) J. H. Best et al. DIABETIC MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search